Approval · Notice of Compliance 25175 · 2021
ULTOMIRIS: Notice of Compliance 25175
Issued February 8, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25175
- Date
- February 8, 2021
- Company
- Alexion Pharma GmbhBaar, --, Switzerland
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a drug substance manufacturing facility
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ULTOMIRIS | Not yet assigned | — |
Medicinal ingredients
- RAVULIZUMAB 10 MG per ML